Strategic partnerships Voyager collaborates with large pharma players (Alexion, AstraZeneca Rare Disease, Novartis, Neurocrine) and maintains a mix of wholly owned and partnered programs, signaling opportunities for co-development, licensing deals, or milestone-based partnerships to expand reach and portfolio.

Neurology focus Pipeline targets multiple CNS diseases including Alzheimer’s, Friedreich’s ataxia, Parkinson’s, ALS, and other CNS conditions, presenting multiple entry points for adjacent indications, platform-enabled gene therapies, and expanded market access through cross-disease applications.

TRACER platform Proprietary TRACER AAV capsid discovery enables high brain penetration with intravenous delivery, indicating potential for collaboration on CNS gene therapy programs, improved delivery solutions, and scalable manufacturing partnerships.

Recent visibility Active participation in AAIC, ASGCT and investor conferences with new GLP toxicology data for VY1706 and multiple poster/oral presentations signals ongoing clinical progress and a pipeline that can generate shared-value marketing, diligence interest, and potential funding opportunities.

Scale and execution Headcount mid-market and substantial funding plus revenue positioning (revenue runway and external funding) suggest capacity to absorb co-development programs, manufacturing scale-up collaborations, and risk-sharing commercial models with strategic partners.